drugset / Trial / NCT06853171

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

NCT06853171

Phase 1 Completed 24 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride in an IR capsule (KarXT) and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders.

Timeline

Start
2025-04-29
Primary completion
2025-07-22
Completion
2025-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule
Subject Xanomeline Small molecule

Indications